Clinical Trial Update: Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FYB206 to pembrolizumab (Keytruda) as add-on to chemotherapy in non-squamous non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• FYB206 (pembrolizumab biosimilar)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Formycon AG | Conditions: Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Status: TERMINATED